Early detection of metastatic uveal melanoma by the analysis of tumor-specific mutations in cell-free plasma DNA.

Detection of ctDNA in plasma can provide a diagnostic lead time over the clinical diagnosis of metastases or tumor recurrence. Longer lead times are to be expected if intervals between sampling are shortened.